A review of uses of health care utilization databases for epidemiologic research on therapeutics

Journal of Clinical Epidemiology

Volumn 58, Issue 4, 2005, Pages 323-337

  Schneeweiss, Sebastian ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adverse drug reactions; Claims data; Confounding (epidemiology); Drug utilization; Pharmaco epidemiology; Therapeuties; Utilization databases

Indexed keywords

ANTIDEPRESSANT AGENT; INSULIN;

ACCURACY; AMBULATORY CARE; CANCER; CHRONIC LIVER DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PHARMACY; CONGESTIVE HEART FAILURE; DATA BASE; DIABETES MELLITUS; DRUG COST; DRUG EXPOSURE; DRUG INFORMATION; DRUG UTILIZATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH SERVICES RESEARCH; HUMAN; HYPERTENSION; KIDNEY FAILURE; MEDICAID; MEDICAL FEE; MEDICAL RECORD; MEDICARE; NEUTROPENIA; OUTCOMES RESEARCH; PEPTIC ULCER; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; STEVENS JOHNSON SYNDROME;

EID: 18044398603     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2004.10.012     Document Type: Article

References (117)

1. J. Avorn Powerful medicines: the benefits, risks, and costs of prescription drugs 2004 Knopf New York
2. The Centers for Education and Research on Therapeutics (CERTs) Risk Assessment Workshop Participants Risk assessment of drugs, biologics and therapeutic devices: present and future issues Pharmacoepidemiol Drug Safety 12 2003 653 662
3. S. Greenland, and W.D. Finkle A retrospective cohort study of implantable medical devices and selected chronic disease in Medicare claims data Ann Epidemiol 10 2000 205 213
4. H.A. Guess Pharmacoepidemiology in pre-approval clinical trial safety monitoring J Clin Epidemiol 44 1991 851 857
5. th ICPE Pharmacoepidemiol Drug Safety 13 2004 S330 S331
6. J. Hallas, D. Gaist, and L. Bjerrum The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization Epidemiology 8 1997 666 670
7. J.S. Benner, R.J. Glynn, H. Mogun, P.J. Neumann, M.C. Weinstein, and J. Avorn Long-term persistence in use of statin therapy in elderly patients JAMA 288 2002 455 461
8. S.B. Soumerai, T.J. McLaughlin, D. Spiegelman, E. Hertzmark, G. Thibault, and L. Goldman Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction JAMA 277 1997 115 121
9. E.L. Knight, and J. Avorn Quality indicators for appropriate medication use in vulnerable elders Ann Intern Med 135 2001 703 710
10. Brookhart MA, Solomon DH, Wang P, Glynn RJ, Avorn J, Schneeweiss S. Quantifying sources of explained variation in multilevel models of therapeutic decision making. J Clin Epidemiol (in press).
11. A.R. Levy, R.M. Tamblyn, P.J. Mcleod, D. Fitchett, and M. Abrahamowicz The effect of physicians' training on prescribing beta-blockers for secondary prevention of myocardial infarction in the elderly Ann Epidemiol 12 2002 86 89
12. R. Tamblyn, P. McLeod, J.A. Hanley, N. Girard, and J. Hurley Physician and practice characteristics associated with the early utilization of new prescription drugs Med Care 41 2003 895 908
13. C.A. Gatsonis, A.M. Epstein, J.P. Newhouse, S.L. Normand, and B.J. McNeil Variations in the utilization of coronary angiography for elderly patients with an acute myocardial infarction: an analysis using hierarchical logistic regression Med Care 33 1995 625 642
14. N. Goldfield Physician profiling and risk adjustment 2nd edition 1999 Aspen Gaithersburg (MD)
15. E.M. Rodriguez, J.A. Staffa, and D.J. Graham The role of databases in drug postmarketing surveillance Pharmacoepidemiol Drug Saf 10 2001 407 410
16. B.L. Strom Sample size considerations for pharmacoepidemiology studies B.L. Strom Pharmacoepidemiology 3rd edition 2000 Wiley Chichester (UK) 31 40
17. L.B. Weatherby, B.L. Nordstrom, D. Fife, and A.M. Walker The impact of wording in "Dear doctor" letters and in black box labels Clin Pharmacol Ther 72 2002 735 742
18. B. Rockhill, B. Newman, and C. Weinberg Use and misuse of population attributable fractions Am J Public Health 88 1998 15 19
19. O.S. Miettinen The need for randomization in the study of intended effects Stat Med 2 1983 267 271
20. B.L. Strom, K.L. Melmon, and O.S. Miettinen Post-marketing studies of drug efficacy: how? Am J Med 77 1984 703 708
21. F. Grodstein, T.B. Clarkson, and J.E. Manson Understanding the divergent data on postmenopausal hormone therapy N Engl J Med 348 2003 645 650
22. A.M. Walker, L.L. Lanza, F. Arellano, and K. Rothman Mortality in current and former users of clozapine Epidemiology 8 1997 671 677
23. The West of Scotland Coronary Preventive Study Group Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study J Clin Epidemiol 48 1995 1441 1452
24. S.B. Soumerai, D. Ross-Degnan, E.E. Fortess, and J. Abelson A critical analysis of studies of state drug reimbursement policies: research in need of discipline Milbank Q 71 1993 217 252
25. R. Tamblyn, R. Laprise, J.A. Hanley, M. Abrahamowicz, S. Scott, N. Mayo, J. Hurley, R. Grad, E. Latimer, R. Perreault, P. McLeod, A. Huang, P. Larochelle, and L. Mallet Adverse events associated with prescription drug cost-sharing among poor and elderly persons JAMA 285 2001 421 429
26. S.B. Soumerai, D. Ross-Degnan, J. Avorn, T. McLaughlin, and I. Choodnovskiy Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes N Engl J Med 325 1991 1072 1077
27. S. Schneeweiss, A.M. Walker, R.J. Glynn, M. Maclure, C. Dormuth, and S.B. Soumerai Outcomes of reference pricing for angiotensin-converting enzyme inhibitors New Engl J Med 346 2002 822 829
28. S. Hennessy, W.B. Bilker, A. Weber, and B.L. Strom Descriptive analyses of the integrity of a US Medicaid claims database Pharmacoepidemiol Drug Saf 12 2003 103 111
29. H.T. Sorenson, S. Sabroe, and J. Olsen A framework for evaluation of secondary data sources for epidemiological research Int J Epidemiol 25 1996 435 442
30. J. Hallas Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis Epidemiology 7 1996 478 484
31. A.M. Walker Confounding by indication Epidemiology 7 1996 335 336
32. R.A. Bright, J. Avorn, and D.E. Everitt Medicaid data as a resource for epidemiologic studies: strengths and limitations J Clin Epidemiol 42 1989 937 945
33. R. Platt, R. Davis, J. Finkelstein, A.S. Go, J.H. Gurwitz, D. Roblin, S. Soumerai, D. Ross-Degnan, S. Andrade, M.J. Goodman, B. Martinson, M.A. Raebel, D. Smith, M. Ulcickas-Yood, and K.A. Chan Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutics Pharmacoepidemiol Drug Saf 10 2001 373 377
34. J.D. Lewis, and C. Brensinger Agreement between GPRD smoking data: a survey of general practitioners and a population-based survey Pharmacoepidemiol Drug Saf 13 2004 437 441
35. H. Jick, G.L. Zornberg, S.S. Jick, S. Seshadri, and D.A. Drachman Statins and the risk of dementia Lancet 356 2000 1627 1631
36. J. Hallas Conducting pharmacoepidemiologic research in Denmark Pharmacoepidemiol Drug Saf 10 2001 619 623
37. S. Schneeweiss, O. Schöffski, and G.W. Selke What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution? Health Policy 44 1998 253 260
38. D.J. Willison Health services research and personal health information: privacy concerns, new legislation, and beyond CMAJ 159 1998 1378 1380
39. L.D. Lynd, L. Warren, M. Maclure, P.D. Paré, and A.H. Anis Using administrative data to recruit study participants while protecting patient privacy: experience with "Camouflaged Sampling" Eur J Epidemiol 19 2004 517 525
40. P.F. Short, D.R. Graefe, and C. Schoen Churn, churn, churn: how instability of health insurance shapes America's uninsured problem. Issue brief 2003 The Commonwealth Fund New York, NY
41. M. Maclure, and S. Schneeweiss Causation of bias: the Episcope Epidemiology 12 2000 114 122
42. A.S. Stergachis Record linkage studies for postmarketing drug surveillance: data quality and validity considerations Drug Intell Clin Pharm 22 1988 157 161
43. A.R. Levy, B.J. O'Brien, C. Sellors, P. Grootendorst, and D. Willison Coding accuracy of administrative drug claims in the Ontario Drug Benefit database Can J Clin Pharmacol 10 2003 67 71
44. D.A. McKenzie, J. Semradek, B.H. McFarland, J.P. Mullooly, and L.E. McCamant The validity of medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience J Clin Epidemiol 53 2000 1248 1257
45. S. West, D.A. Savitz, G. Koch, B.L. Strom, H.A. Guess, and A. Hartzema Recall accuracy for prescription medications: self report compared with database information Am J Epidemiol 142 1995 1103 1112
46. S. West, B.L. Strom, B. Freundlich, E. Normand, G. Koch, and D.A. Savitz Completeness of prescription recording in outpatients medical records from a health maintenance organization J Clin Epidemiol 47 1994 165 171
47. WHO Collaborating Centre for Drug Statistics Methodology ATC index with DDD 2003 WHO Oslo, Norway
48. A.D. McMahon, J.M. Evans, and M.M. McGilchrist Drug exposure risk windows and unexposed comparator groups for cohort studies in Pharmacoepidemiology Pharmacoepidemiol Drug Safety 7 1998 275 280
49. C. Dormuth, and S. Schneeweiss Rapid monitoring of drug discontinuation rates in response to restrictions in drug reimbursement Pharmacoepidemiol Drug Saf 13 2004 5310 5311
50. S. Jacobus, S. Schneeweiss, and K.A. Chan Exposure misclassification as a result of free sample drug utilization in automated claims databases and its effect on pharmacoepidemiologic studies of selective COX-2 inhibitors Pharmacoepidemiol Drug Safety 13 2004 695 702
51. H.A. Guess Behavior of the exposure odds ratio in a case-control study when the hazard function is not constant over time J Clin Epidemiol 42 1989 1179 1184
52. J.L. Kelsey, A.S. Whittemore, A.S. Evans, and W.D. Thompson Methods in observational epidemiology 2nd edition 1996 Oxford University Press New York
53. M. Wilchesky, R.M. Tamblyn, and A. Huang Validation of diagnostic codes within medical services claims J Clin Epidemiol 57 2004 131 141
54. P.S. Romano, and D.H. Mark Bias in the coding of hospital discharge data and its implications for quality assessment Med Care 32 1994 81 90
55. Y. Kiyota, S. Schneeweiss, R.J. Glynn, C.C. Cannuscio, J. Avorn, and D.H. Solomon The accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value based on review of hospital records Am Heart J 148 2004 99 104
56. C.R. Meier, S.S. Jick, L.E. Derby, C. Vasilakis, and H. Jick Acute respiratory-tract infections and risk of first-time acute myocardial infarction Lancet 351 1998 1467 1471
57. D.H. Solomon, S. Schneeweiss, R.J. Glynn, Y. Kiyota, R. Levin, H. Mogun, and J. Avorn The relationship between selective COX-2 inhibitors and acute myocardial infarction Circulation 109 2004 2068 2073
58. F. Barbone, A.D. McMahon, P.G. Davey, A.D. Morris, I.C. Reid, D.G. McDevitt, and T.M. MacDonald Association of road-traffic accidents with benzodiazepine use Lancet 352 1998 1331 1336
59. R.A. Deyo, D.C. Cherkin, and M.A. Ciol Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases J Clin Epidemiol 45 1992 613 619
60. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chron Dis 40 1987 373 383
61. S. Schneeweiss, J. Seeger, M. Maclure, P. Wang, J. Avorn, and R.J. Glynn Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data Am J Epidemiol 154 2001 854 864
62. H. Quan, G.A. Parsons, and W.A. Ghali Assessing accuracy of diagnosis-type indicators for flagging complications in administrative data J Clin Epidemiol 57 2004 366 372
63. K.T. Copeland, H. Checkoway, R.H. Holbrook, and A.J. McMichael Bias due to misclassification in the estimate of relative risk Am J Epidemiol 105 1977 488 495
64. S. Greenland The effect of misclassification in matched-pair case-control studies Am J Epidemiol 116 1982 402 406
65. R.J. Marshall Validation study methods for estimating exposure proportions and odds ratios with misclassified data J Clin Epidemiol 43 1990 941 947
66. H. Brenner, and O. Gefeller Use of positive predictive value to correct for disease misclassification in epidemiologic studies Am J Epidemiol 138 1993 1007 1015
67. J.R. Cook, and L.A. Stefanski Simulation-extrapolation estimation in parametric measurement error models J Am Stat Assoc 89 1994 1314 1328
68. L.A. Stefanski, and J.R. Cook Simulation-extrapolation: the measurement error jackknife J Am Stat Assoc 90 1995 1247 1256
69. S. Schneeweiss, D.L. Spiegelman, J. Avorn, and R.J. Glynn Sensitivity of multivariate logistic regression results towards random misclassification of exposure status and event dates in a study on antiparkinsonian drug use and sudden onset pathologic somnolence Pharmacoepidemiol Drug Safety 12 2003 S146 S147
70. S. Schneeweiss, R.J. Glynn, J. Avorn, and D.H. Solomon A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for cox-2 inhibitors J Clin Epidemiol 58 2005 98 102
71. K.J. Rothman, and S. Greenland Modern epidemiology 2nd edition 1998 Lippincott Williams & Wilkins Philadelphia
72. P. Peduzzi, J. Concato, E. Kemper, T.R. Holford, and A.R. Feinstein A simulation study of the number of events per variable in logistic regression analysis J Clin Epidemiol 49 1996 1373 1379
73. O.S. Miettinen Stratification by a multivariate confounder score Am J Epidemiol 104 1976 609 620
74. P.R. Rosenbaum, and D.B. Rubin The central role of the propensity score in observational studies for causal effects Biometrika 70 1983 41 55
75. S. Weitzen, K.L. Lapane, A.Y. Toledano, A.L. Hume, and V. Mor Principles for modeling propensity scores in medical research: a systematic literature review Pharmacoepidemiol Drug Safety 13 2004 841 853
76. D.B. Rubin Estimating causal effects from large data sets using propensity scores Ann Intern Med 127 1997 757 763
77. L.E. Braitman, and P.R. Rosenbaum Rare outcomes, common treatments: analytic strategies using propensity scores Ann Intern Med 137 2002 693 695
78. M.S. Cepeda, R. Boston, J.T. Farrar, and B.L. Strom Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders Am J Epidemiol 158 2003 280 287
79. W.A. Ray, C.M. Stein, K. Hall, J.R. Daugherty, and M.R. Griffin Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study Lancet 359 2002 118 123
80. E.F. Cook, and L. Goldman Performance of tests of significance based on stratification by a multivariate confounder score or by a propensity score J Clin Epidemiol 42 1989 317 324
81. R.J. Glynn, E.L. Knight, R. Levin, and J. Avorn Paradoxical relations of drug treatment with mortality in older persons Epidemiology 12 2001 682 689
82. S. Schneeweiss, and P. Wang Association between SSRI use and hip fractures and the effect of residual confounding bias in claims database studies J Clin Psychopharm 13 2004 695 702
83. J.P. Vandenbroucke When are observational studies as credible as randomized trials? Lancet 363 2004 1728 1731
84. W.A. Ray Evaluating medication effects outside of clinical trials: new-user designs Am J Epidemiol 158 2003 915 920
85. E. Giovannucci, K.M. Egan, D.J. Hunter, M.J. Stampfer, G.A. Colditz, W.C. Willett, and F.E. Speizer Aspirin and the risk of colorectal cancer in women N Engl J Med 333 1995 609 614
86. S. Schneeweiss, R.J. Glynn, E.H. Tsai, J. Avorn, and D.H. Solomon Assessment of bias by unmeasured confounders in pharmacoepidemiologic claims data studies using external data Epidemiology 16 2005 17 24
87. P. Velentgas, C. Cali, G. Diedrick, M.J. Heinen, K.M. Verburg, N.A. Dreyer, and A.M. Walker A survey of aspirin use, non-prescription NSAID use, and cigarette smoking among users and non-users of prescription NSAIDs: estimates of the effect of unmeasured confounding by these factors on studies of NSAID use and risk of myocardial infarction Pharmacoepidemiol Drug Safety 10 2001 S103
88. S. Suissa Relative excess risk: an alternative measure of comparative risk Am J Epidemiol 150 1999 279 282
89. B.M. Psaty, T.D. Koepsell, D. Lin, N.S. Weiss, D.S. Siscovick, F.R. Rosendaal, M. Pahor, and C.D. Furberg Assessment and control for confounding by indication in observational studies J Am Geriatr Soc 47 1999 749 754
90. T.L. Lash, and A.K. Fink Semi-automated sensitivity analysis to assess systematic errors in observational data Epidemiology 14 2003 451 458
91. D. Saliba, M. Orlando, N.S. Wenger, R.D. Hays, and L.Z. Rubenstein Identifying a short functional disability screen for older persons J Gerontol 55 2000 750 756
92. F.J. Eppig, G.S. Chulis, and M.C.B.S. Matching Medicare data: the best of both worlds Health Care Financing Rev 18 1997 211 229
93. T. Sturmer, S. Schneeweiss, J. Avorn, and R.J. Glynn Correcting effect estimates for unmeasured confounding in cohort studies with validation studies using propensity score calibration Am J Epidemiol 2004 in press
94. B. Rosner, D. Spiegelman, and W.C. Willett Correction of logistic regression relative risk estimates and confidence intervals for measurement error: the case of multiple covariates measured with error Am J Epidemiol 132 1990 734 745
95. M. Maclure The case-crossover design: a method for studying transient effects on the risk of acute events Am J Epidemiol 133 1991 144 153
96. J. Hallas Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis Epidemiology 7 1996 478 484
97. R. Hubbard, P. Farrington, C. Smith, L. Smeeth, and A. Tattersfield Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture Am J Epidemiol 158 2003 77 84
98. C.P. Farrington Relative incidence estimation from case series for vaccine safety evaluation Biometrics 51 1995 228 235
99. S.K. Vines, and C.P. Farrington Within-subject exposure dependency in case-crossover studies Stat Med 20 2001 3039 3049
100. P.S. Wang, S. Schneeweiss, R.J. Glynn, H. Mogun, and J. Avorn Use of the case-crossover design to study prolonged drug exposures and insidious outcomes Ann Epidemiol 14 2004 296 303
101. S. Suissa The case-time-control design Epidemiology 6 1995 248 253
102. S. Suissa The case-time-control design: further assumptions and conditions Epidemiology 9 1998 441 445
103. M. McClellan, B.J. McNeil, and J.P. Newhouse Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables JAMA 272 1994 859 866
104. J.P. Newhouse, and M. McClellan Econometrics in outcomes research: the use of instrumental variables Annu Rev Public Health 19 1998 17 34
105. S. Schneeweiss, M. Maclure, S.B. Soumerai, A.M. Walker, and R.J. Glynn Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance J Clin Epidemiol 55 2002 833 841
106. W.A. Ray Policy and program analysis using administrative databases Ann Intern Med 127 1997 712 718
107. H. Jick, S.S. Jick, and L.E. Derby Validation of information recorded on general practitioner based computerised data resource in the United Kingdom Br Med J 302 1991 766 768
108. D.P. Miller, T. Alfredson, S.F. Cook, B.E. Sands, and A.M. Walker Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride Am J Gastroenterol 98 2003 1117 1122
109. K.-Y. Liang, and S.L. Zeger Longitudinal data analysis using generalized linear models Biometrika 73 1986 13 22
110. T. Snijders, and R. Bosker Multilevel analysis 1999 Sage London
111. J.W.R. Twisk Applied longitudinal data analysis for epidemiology 2003 Cambridge University Press Cambridge, UK
112. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, and E. Vittinghoff Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group JAMA 280 1998 605 613
113. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, R.D. Jackson, S.A. Beresford, B.V. Howard, K.C. Johnson, J.M. Kotchen, J. Ockene, and Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
114. F. Grodstein, J.E. Manson, G.A. Colditz, W.C. Willett, F.E. Speizer, and M.J. Stampfer A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease Ann Intern Med 133 2000 933 941
115. M. Mamdani, P. Rochon, D.N. Juurlink, G.M. Anderson, A. Kopp, G. Naglie, P.C. Austin, and A. Laupacis Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly Arch Intern Med 163 2003 481 486
116. E.S. Fisher, F.S. Whaley, M. Krushat, D.J. Malenka, C. Fleming, J.A. Barin, and D.C. Hsia The accuracy of Medicare's hospital claims data: progress has been made, but problems remain Am J Public Health 82 1992 243 248
117. B.L. Strom Data validation issues in using claims data Pharmacoepidemiol Drug Safety 10 2001 389 392